GlassScriptPhysician profile
Ines I Mbaga
NPI 1710056296
$1,817.99
in general payments reported to CMS, 2019-2025
14 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $57.75 · 2021: $203 · 2022: $249 · 2023: $380 · 2024: $266 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $459.97 | 2020-2025 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $284.27 | 2019-2025 | Vibativ |
| Gilead Sciences, INC. | $222.62 | 2019-2024 | |
| Insmed, INC. | $131.69 | 2021-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $124.25 | 2023-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $103.27 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Astellas Pharma US INC | $102.80 | 2021-2022 | |
| Viiv Healthcare Company | $92.61 | 2019-2024 | Apretude |
| Medtronic Vascular, INC. | $77.78 | 2019 | |
| Abbvie INC. | $74.33 | 2022-2023 | |
| Philips North America LLC | $73.81 | 2019 | |
| Janssen Biotech, INC. | $43.54 | 2019 | |
| Mylan Institutional INC. | $13.55 | 2019 | |
| Allergan, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ines Mbaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.